Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review ; volume:26 ; number:12 ; day:27 ; month:11 ; year:2024 ; pages:1651-1663 ; date:12.2024
Current oncology reports ; 26, Heft 12 (27.11.2024), 1651-1663, 12.2024
- Creator
-
Kalsi, Simran
Galenkamp, Amanda L.
Singh, Rohit
Khosla, Atulya Aman
McGranaghan, Peter
Cintolo-Gonzalez, Jessica
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-024-01611-9
- URN
-
urn:nbn:de:101:1-2502262108482.278046042388
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kalsi, Simran
- Galenkamp, Amanda L.
- Singh, Rohit
- Khosla, Atulya Aman
- McGranaghan, Peter
- Cintolo-Gonzalez, Jessica
- SpringerLink (Online service)
Other Objects (12)
Emerging Immunotherapies for Parkinson Disease
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
CAR-Immunotherapies for the treatment of metastatic rhabdomyosarcomas
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Potentials and limitations of current and emerging immunotherapies
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Pěší věc
Vĕc mys̆lení
Emerging Immunotherapies for Parkinson Disease
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
CAR-Immunotherapies for the treatment of metastatic rhabdomyosarcomas
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Potentials and limitations of current and emerging immunotherapies
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Pěší věc
Vĕc mys̆lení
Emerging Immunotherapies for Parkinson Disease
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
CAR-Immunotherapies for the treatment of metastatic rhabdomyosarcomas
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Potentials and limitations of current and emerging immunotherapies
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Pěší věc